New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
10:00 EDTABY, BSX, DWA, ELGX, LXU, EVAR, LGF, STJ, ZFGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with a Neutral at HSBC... Boston Scientific (BSX) initiated with a Neutral at Sterne Agee... DreamWorks Animation (DWA) initiated with a Market Perform at FBR Capital... Endologix (ELGX) initiated with an Outperform at Credit Suisse... LSB Industries (LXU) initiated with a Buy at Feltl... Lionsgate (LGF) initiated with an Outperform at FBR Capital... Lombard Medical (EVAR) initiated with an Outperform at Credit Suisse... St. Jude Medical (STJ) initiated with a Neutral at Sterne Agee... Zafgen (ZFGN) initiated with an Outperform at JMP Securities.
News For ABY;BSX;DWA;ELGX;LXU;EVAR;LGF;STJ;ZFGN From The Last 14 Days
Check below for free stories on ABY;BSX;DWA;ELGX;LXU;EVAR;LGF;STJ;ZFGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 17, 2014
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information
September 16, 2014
09:59 EDTLGFOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ACI Worldwide (ACIW) initiated with a Neutral at Sterne Agee... ADP (ADP) initiated with a Market Perform at Bernstein... ANSYS (ANSS) initiated with a Sector Perform at RBC Capital... Accenture (ACN) initiated with a Market Perform at Bernstein... Blackhawk (HAWK) initiated with a Neutral at Sterne Agee... Coca-Cola (KO) initiated with a Market Perform at Cowen... Cognizant (CTSH) initiated with an Outperform at Bernstein... Constellation Brands (STZ) initiated with a Market Perform at Cowen... Dr Pepper Snapple (DPS) initiated with a Market Perform at Cowen... GenCorp (GY) initiated with a Hold at KeyBanc... Global Payments (GPN) initiated with a Neutral at Piper Jaffray... GoPro (GPRO) initiated with a Buy at Cleveland Research... Green Dot (GDOT) initiated with a Neutral at Sterne Agee... Lionsgate (LGF) initiated with a Buy at ISI Group... MEDNAX (MD) initiated with a Neutral at SunTrust... MasterCard (MA) initiated with a Buy at Sterne Agee... Molson Coors (TAP) initiated with an Outperform at Cowen... Monster Beverage (MNST) initiated with a Market Perform at Cowen... NetSuite (N) initiated with an Outperform at RBC Capital... Oracle (ORCL) assumed with a Sector Perform at RBC Capital... PepsiCo (PEP) initiated with an Outperform at Cowen... SAP (SAP) initiated with a Sector Perform at RBC Capital... Teekay (TK) initiated with a Hold at Deutsche Bank... Tesla (TSLA) initiated with a Buy at ISI Group... Visa (V) initiated with a Buy at Sterne Agee... Western Union (WU) initiated with a Neutral at Sterne Agee... Workday (WDAY) initiated with an Outperform at RBC Capital... Yelp (YELP) initiated with a Neutral at RW Baird... Zillow (Z) initiated with an Overweight at Stephens... zulily (ZU) initiated with an Outperform at RW Baird.
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
07:27 EDTDWABofA/Merrill to hold a conference
Subscribe for More Information
05:15 EDTSTJData shows PA pressure monitoring did not adversely affect kidney function
Subscribe for More Information
September 15, 2014
16:10 EDTLGFLionsgate initiated with a Buy at ISI Group
Subscribe for More Information
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
08:02 EDTSTJSt. Jude Medical announces launch of OPTISTM integrated system
St. Jude Medical announced the company has secured CE Mark and FDA clearance for the new OPTISTM Integrated System. The system is a departure from traditional, mobile cart-based diagnostic tools and advances percutaneous coronary intervention optimization via direct installation into a hospitalís cardiac catheterization laboratory, fully integrating optical coherence tomography and fractional flow reserve into PCI workflow.
07:45 EDTBSX, STJCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:21 EDTSTJHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 13, 2014
18:16 EDTSTJSt. Jude Medical announces data from the EnligHTN III study
St. Jude Medical announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. The results were presented during the 26th annual Transcatheter Cardiovascular Therapeutics scientific symposium.
September 12, 2014
15:03 EDTSTJ, BSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 10, 2014
07:31 EDTLGFGoldman to hold a conference
Subscribe for More Information
September 8, 2014
10:03 EDTLGFLionsgate says Lionsgate UK to assume distribution of Summit films
Lionsgate announced that Lionsgate UK will assume responsibility for the distribution of all Summit label films and will integrate them with the Lionsgate, third-party and locally-produced films it already distributes. The expanded distribution will begin with Summit label films produced after July 2015. The move follows last month's announcement that Lionsgate has moved its international sales headquarters to London. Lionsgate UK's distribution of Summit releases will include Allegiant Part 2, the fourth film in the Divergent franchise, which is slated to begin production in 2016 for worldwide release on March 24, 2017. Distribution of Summit titles in the UK was previously handled by eOne Entertainment. eOne and Lionsgate announced last week that they are extending and expanding their partnership in three territories, with eOne continuing to distribute Lionsgate and Summit films in Canada and Spain and Summit titles in Australia through 2018.
10:03 EDTLGFLionsgate UK expands distribution operations
Subscribe for More Information
08:03 EDTLGFLionsgate increases quarterly dividend to 7c from 5c
e dividend is payable on November 7 to shareholders of record as of September 30.
07:26 EDTSTJ, BSXMorgan Stanley to hold a conference
Subscribe for More Information
07:21 EDTLXUKeyBanc to hold a conference
2014 Basic Materials & Packaging Conference to be held in Boston on September 8-10.
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use